We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+33.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.42B
AUM Growth
+$877M
(+19%)
Cap. Flow
-$870M
Cap. Flow
% of AUM
-16.07%
Top 10 Holdings %
Top 10 Hldgs %
57.84%
Holding
236
New
154
Increased
21
Reduced
12
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oscar Health
OSCR
|
+$77.6M |
| 2 |
Baxter International
BAX
|
+$48.1M |
| 3 |
Revolution Medicines
RVMD
|
+$32.2M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$26.2M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$22.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$38.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$36M |
| 3 |
ACH
Accendra Health
ACH
|
+$21.8M |
| 4 |
MRUS
Merus
MRUS
|
+$20M |
| 5 |
Roivant Sciences
ROIV
|
+$18.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.17% |
| 2 | Technology | 0.1% |
| 3 | Industrials | 0.09% |
| 4 | Consumer Discretionary | 0.08% |
| 5 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cabaletta Bio
CABA
$461M
| $45.6M | 0.84% |
2,007,729
-332,389
| -14% | -$5.59M |
|
27
Edgewise Therapeutics
EWTX
$4.28B
| $43M | 0.79% |
3,933,137
| – | – |
|
28
Insulet
PODD
$11.4B
| $38.8M | 0.72% |
178,920
+51,920
| +41% | +$8.91M |
|
29
Structure Therapeutics
GPCR
$3.45B
| $33.5M | 0.62% |
822,813
+195,000
| +31% | +$11.2M |
|
30
Alignment Healthcare
ALHC
$4.26B
| $30M | 0.55% |
3,488,808
+741,793
| +27% | +$5.43M |
|
31
DocGo
DCGO
$64.3M
| $29.7M | 0.55% |
5,320,139
+556,139
| +12% | +$3.19M |
|
32
BioCryst Pharmaceuticals
BCRX
$2.36B
| $27.2M | 0.5% |
4,539,525
+1,253,525
| +38% | +$7.26M |
|
33
Disc Medicine
IRON
$2.91B
| $26.8M | 0.5% |
464,292
+34,292
| +8% | +$1.76M |
|
34
Embecta
EMBC
$193M
| $26.2M | 0.48% |
+1,384,839
| New | +$22.7M |
|
|
DAWN
35
DELISTED
Day One Biopharmaceuticals
DAWN
| $25.7M | 0.47% |
1,761,178
+491,186
| +39% | +$5.95M |
|
36
QuidelOrtho
QDEL
$1.19B
| $25.6M | 0.47% |
348,000
+198,000
| +132% | +$13.4M |
|
|
LKFT
37
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
| $25.3M | 0.47% |
+622,112
| New | +$22.9M |
|
38
Viking Therapeutics
VKTX
$4.31B
| $23.8M | 0.44% |
1,279,000
| – | – |
|
39
Pharvaris
PHVS
$2.44B
| $22.8M | 0.42% |
+812,236
| New | +$16.4M |
|
40
Nkarta
NKTX
$186M
| $22.4M | 0.41% |
+3,400,000
| New | +$8.81M |
|
41
Guardant Health
GH
$20.7B
| $21.4M | 0.4% |
791,735
-538,200
| -40% | -$14.1M |
|
42
Castle Biosciences
CSTL
$733M
| $20.8M | 0.38% |
965,428
+18,808
| +2% | +$331K |
|
43
Prelude Therapeutics
PRLD
$335M
| $17.6M | 0.33% |
+4,133,000
| New | +$12.6M |
|
44
Replimune Group
REPL
$859M
| $15.3M | 0.28% |
+1,811,710
| New | +$21M |
|
45
Tango Therapeutics
TNGX
$4.65B
| $15.2M | 0.28% |
1,540,000
+746,271
| +94% | +$6.48M |
|
46
Verastem
VSTM
$530M
| $12.5M | 0.23% |
1,538,461
| – | – |
|
47
Alector
ALEC
$167M
| $8.52M | 0.16% |
1,067,810
+12,618
| +1% | +$74.8K |
|
|
ITOS
48
DELISTED
iTeos Therapeutics
ITOS
| $7.92M | 0.15% |
723,000
| – | – |
|
|
CMAX
49
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $7.91M | 0.15% |
529,107
| – | – |
|
50
Prime Medicine
PRME
$565M
| $7.84M | 0.14% |
885,314
| – | – |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q4 2023 Portfolio in Review
As of Q4 2023, Deerfield Management held 236 positions worth $5.42B, up 19% from $4.54B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Deerfield Management withdrew a net $870M in Q4 2023, closing 14 positions and reducing 12 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $38.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 68% a quarter earlier, followed by Technology and Industrials.
Against the trend, Deerfield Management opened a new position in Oscar Health worth $103M.
- Deerfield Management's largest Q4 2023 buy was Oscar Health: 11,246,820 shares worth $103M.
- Deerfield Management added most to Revolution Medicines in Q4 2023, an estimated $32.2M increase.
- Deerfield Management's biggest Q4 2023 reduction was Neurocrine Biosciences, cutting an estimated $36M.
- Deerfield Management fully exited Intercept Pharmaceuticals, Inc. in Q4 2023, selling an estimated $38.5M.
- Deerfield Management's ten largest holdings make up 58% of its $5.42B portfolio in Q4 2023.
- Deerfield Management opened 154 new positions and closed 14 in Q4 2023.
- Deerfield Management's portfolio value rose 19% quarter-over-quarter to $5.42B.
Based on Deerfield Management's 13F filing for Q4 2023, filed 14 Feb 2024.